Jaguar Animal Health ( (JAGX) ) just unveiled an update.
On March 31, 2025, Jaguar Health closed a private placement, raising approximately $3.448 million through convertible promissory notes and warrants. The funds will be used for working capital and general corporate purposes, with expectations of key catalysts in the second quarter of 2025 related to crofelemer development for rare diseases and cancer therapy-related diarrhea, potentially enhancing the company’s value.
More about Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company that develops novel proprietary prescription medicines derived from plants in rainforest areas. The company focuses on treating gastrointestinal distress, including chronic diarrhea and bowel incontinence. Its subsidiary, Napo Pharmaceuticals, develops human prescription pharmaceuticals for neglected gastrointestinal symptoms, with crofelemer being FDA-approved for noninfectious diarrhea in adults with HIV/AIDS. Napo Therapeutics, established in Milan, Italy, aims to expand crofelemer access in Europe for rare diseases.
YTD Price Performance: -81.98%
Average Trading Volume: 24,174
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.07M
Find detailed analytics on JAGX stock on TipRanks’ Stock Analysis page.